Ligand Reports Third Quarter 2019 Financial Results
Ligand to Report Third Quarter 2019 Results on November 5th
Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors
Ligand to Participate in the H. C. Wainwright 21st Annual Global Investment Conference
Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China
Ligand Reports Second Quarter 2019 Financial Results
Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company
Ligand to Report Second Quarter 2019 Results on July 30th
Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
ZULRESSO™ (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligand’s Captisol® in its Formulation, Launched by Sage Therapeutics
Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target
Ligand Licenses VER250840 to Cumulus Oncology
Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.
